Drug induced liver injury secondary to interferon-beta (IFN-B) in multiple sclerosis

Post marketing studies of Interferon-β (IFNβ) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity. Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFNβ. We report three cases of IFNβ ββ β β induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.